Key result
Genetic polymorphisms in CYP3A5, ABCB1, and other enzymes influence apixaban pharmacokinetics and safety, highlighting the need for personalized anticoagulant therapy.
Why the study?
Studies have documented individual variability in plasma DOAC levels, creating a need to understand the role of pharmacogenetics in adapting anticoagulant therapy according to patient genetic characteristics.
Does a pharmacogenetic approach predict individual pharmacokinetics and the safety profile of apixaban?
Does a pharmacogenetic approach predict individual pharmacokinetics and the safety profile of apixaban?
Pharmacogenetic profiling of enzymes like CYP3A5 and transporters like ABCB1 could help predict apixaban pharmacokinetics and personalize dosing to minimize bleeding risks.
Answers are grounded in this paper and cite their sources.
DOAC plasma level variability leaves open a role for pharmacogenetics in therapy adaptation; prospective trials needed before clinical use.
In recent years, there has been a trend towards increased prescribing of direct-acting oral anticoagulants (DOACs) due to favourable pharmacokinetics and pharmacodynamics without the need for regular coagulation monitoring. However, recent studies have documented individual variability in plasma DOAC levels. DOAC pharmacogenetics is a relatively new area of research. There is a need to understand the role of pharmacogenetics in the adaptation of anticoagulant therapy according to a patient’s genetic characteristics. This scientific review of current data on the impact of different gene polymorphisms on apixaban pharmacokinetics broadens the understanding of the clinical relevance of genotyping for treatment efficacy and safety.
No takes yet. Share an insight, caveat, or question.
Fedina et al. (2022) conducted a review in Atrial fibrillation / Apixaban therapy. Pharmacogenetic variations (CYP3A5, ABCB1) was evaluated. Genetic polymorphisms in CYP3A5, ABCB1, and other enzymes influence apixaban pharmacokinetics and safety, highlighting the need for personalized anticoagulant therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: